Clinical Trials
103 trialsCarmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
City of Hope Medical Center
DS-3201b in Participants With Lymphomas
Daiichi Sankyo
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Kyowa Kirin Co., Ltd.
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
St. Jude Children's Research Hospital
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
UNC Lineberger Comprehensive Cancer Center
ON-5001
OncoNano Medicine, Inc.
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
Treeline Biosciences, Inc.
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
SciTech Development, Inc.
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
Ohio State University Comprehensive Cancer Center
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
Novartis
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
National Cancer Institute (NCI)
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Pfizer
Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101
Eisai Inc.
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
TopAlliance Biosciences
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Rutgers, The State University of New Jersey
Safety Study of SEA-CD40 in Cancer Patients
Seagen Inc.
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
A Study of PNT2258 in Patients With Advanced Solid Tumors
Sierra Oncology LLC - a GSK company
GEN602
Genzada Pharmaceuticals USA, Inc.
RPTR-147 in Patients With Selected Solid Tumors and Lymphomas
Repertoire Immune Medicines
Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
National Institutes of Health Clinical Center (CC)
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer
Jonsson Comprehensive Cancer Center
Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma
University of California, San Francisco
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative
Memorial Sloan Kettering Cancer Center
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
Tocagen Inc.
Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Acrotech Biopharma Inc.
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
University of Wisconsin, Madison
Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma
University of Wisconsin, Madison
Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome
Northwestern University
Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma
Mayo Clinic
Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer
Swiss Cancer Institute
Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides
Case Comprehensive Cancer Center
Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
M.D. Anderson Cancer Center
LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab
Lytix Biopharma AS
Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma
Celgene
Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies
Celgene
NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
Celgene
Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
University of California, San Francisco
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Massachusetts General Hospital
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection
Mirna Therapeutics, Inc.
Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy
National Institutes of Health Clinical Center (CC)
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
Alliance for Clinical Trials in Oncology
SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma
Progen Pharmaceuticals
BAY1238097, First in Man
Bayer
Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
Case Comprehensive Cancer Center
IFNa
The Cleveland Clinic
Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment
City of Hope Medical Center
UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma
National Cancer Institute (NCI)